Zika virus: antibodies identified with therapeutic and diagnostic potential
Institutional Communication Service
14 July 2016
A team of researchers from IRB and the Swiss biotech company Humabs BioMed has identified novel therapeutic monoclonal antibody candidates isolated from Zika-infected patients and new strategies for Zika virus diagnostics. An article published today in the renowned journal Science describes for the first time an in-depth analysis of the human antibody with important implications for differential diagnostics and for the development of vaccines and new treatments.
The study is the result of an international collaboration with the University of California, Berkeley (US), Public Health England, Porton Down (UK), the Policlinico San Matteo IRCCS, Pavia (IT), the Swiss Tropical and Public Health Institute, Basel (CH), and the Centre for Tropical Medicine, Ho Chi Minh City (VN). The study was partially funded by the Swiss National Science Foundation, the European Research Council, the US National Institutes of Health and the Italian Ministry of Health.
Zika virus is a mosquito-borne flavivirus with homology to Dengue virus. After its introduction into Brazil in 2015, Zika virus has spread rapidly in Latin America and in February 2016, the World Health Organization (WHO) declared it a Public Health Emergency of International Concern. While the main route of Zika virus infection is through bites by mosquitos, the virus may also be spread sexually and vertically from mother to child during the first months of pregnancy. Most of the Zika virus infections are asymptomatic or cause only mild symptoms. However, Zika virus infection can lead to congenital birth defects such as microcephaly. As of today, there is no preventive vaccine or specific therapy available.
The study published in Science reports the first characterization of the human immune response to Zika infection, showing that most of the antibodies elicited by Zika virus infection cross-react with Dengue virus. These cross-reactive antibodies are poorly neutralizing, and can increase the severity of subsequent infection with Zika or Dengue virus. The study shows in experimental models that cross-reactive antibodies induced by infection with Zika virus are capable of provoking lethal Dengue virus infections. These findings, which are subject to validation by prospective epidemiological studies, should be taken into consideration in the context of the development of vaccines.
It took only four months to functionally select, clone and characterize more than 100 anti-Zika virus antibodies from the initial screening of human B cells derived from four convalescent patients. The most potent antibody capable to neutralize Zika virus is now being developed by Humabs BioMed to prevent congenital infections.
"I believe that our discoveries will also have a significant impact on the development of novel diagnostic to differentiate between a Zika or a Dengue infection" said Davide Corti, CSO and senior VP, Humabs.
"This study represents another example of the rapid pathway established at Humabs for the isolation and characterization of large numbers of antibodies directed against infectious agents and for the development of the best in class antibodies as potential new therapies against emerging pathogens," said Filippo Riva, CEO of Humabs.
“In contrast to the broad cross-reactivity observed with antibodies, we found that the T cell response is to a large extent Zika-specific, a finding that may decrease the risk of Dengue infection in Zika-immunized individuals”, said Federica Sallusto, Director of the Center of Medical Immunology at the Institute for Research in Biomedicine (IRB).
The study also illustrates the use of some of the Zika virus-specific antibodies isolated in serological diagnostic tests in large cohort clinical and epidemiological studies to investigate the risk of Zika virus disease enhancement in subjects pre-immunized with other flavivirus such as the Dengue virus and the real incidence rate of Zika virus congenital infection in Zika infection endemic areas.
A highly potent neutralizing antibody was identified and engineered into the "LALA" form to not bind the Fc receptors, which is normally the pathway to promote the infection and multiplication of the virus. This LALA antibody showed to inhibit the increase of Zika virus infection caused by antibodies present in the serum of subjects immune to Dengue or Zika virus and showed prophylactic and therapeutic efficacy in a lethal infection model of Zika virus.
This class of highly potent engineered LALA antibodies holds the promise of preventing congenital Zika virus infection in pregnant women at risk, and also to serve as potential inhibitors of disease enhancement and transplacental infection by pre-existing cross-reactive antibodies.
Dr. Davide Corti, CSO
Tel +41 91 825 63 80
Email [email protected]
The Institute for Research in Biomedicine (IRB) was founded in 2000 in Bellinzona and was affiliated to the Università della Svizzera italiana (USI) in 2010. Financed by private and public institutions and by competitive grants, the IRB currently hosts 10 research groups and 105 researchers that investigate the mechanisms of host defense against infectious agents, cancer and degenerative diseases. With more than 460 publications in leading scientific journals, the IRB has gained an international reputation as a center of excellence in human immunology. Antonio Lanzavecchia, Director of the IRB and Professor at the ETH Zurich, is inventor of the technology for the production of monoclonal antibodies from human memory B cells that has been exclusively licensed to Humabs BioMed.
About Humabs BioMed SA
Humabs BioMed is a leading Swiss antibody therapeutics company, which is a spin-off of the Institute for Research in Biomedicine (IRB), that rapidly discovers and develops superior antibodies directly derived from individuals who have successfully overcome major diseases. These "winner antibodies" have already passed natural selection by the immune system in response to disease and can easily be developed for standardized therapeutic use. The technologies that enable the isolation of human antibodies have been developed at the IRB by Professor Antonio Lanzavecchia and have been licensed to Humabs for commercial use. The company currently focuses on infectious diseases, but also has selected antibodies against inflammatory diseases in the pipeline. To date, the company has closed four major licensing deals with top pharmaceutical companies. Two of these programs, partnered with MedImmune and Novartis, respectively, are currently in clinical development for the therapy of important viral infection.